Holen Sie sich die Stockscreener-App
12.02
0.42%
0.05
Schlusskurs vom Vortag:
$11.97
Offen:
$12
24-Stunden-Volumen:
1.08M
Relative Volume:
0.57
Marktkapitalisierung:
$1.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-5.5392
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+0.25%
1M Leistung:
+20.68%
6M Leistung:
+86.36%
1J Leistung:
+9.87%
1-Tages-Spanne:
$11.95
$12.32
1-Wochen-Bereich:
$10.80
$12.32
52-Wochen-Spanne:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
12.02 | 1.04B | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
FDA approved five NMEs in November - biocentury.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
Kura Oncology (NASDAQ:KURA) Trading Up 7.3%What's Next? - MarketBeat
Kura Oncology: A Cautious Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Kura Oncology to Host Virtual Investor Event to Discuss - GlobeNewswire
Geode Capital Management LLC Purchases 211,470 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (KURA) Is Down 7.2% After First KOMZIFTI Sale Triggers $135M Milestone Payment - simplywall.st
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA) - Seeking Alpha
Kura Oncology, Inc. Completes Collaboration and License Agreement with Kyowa Kirin - marketscreener.com
Kura Oncology Expects $135 Million Milestone Payment for First US Sale of Komzifti - marketscreener.com
Kura Oncology (KURA) Secures $135 Million Milestone with KOMZIFT - GuruFocus
Kura Oncology completes first commercial sale of leukemia drug - Investing.com
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - TipRanks
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment - Investing.com
Kura Oncology Announces First U.S. Sale of KOMZIFTI - TipRanks
Kura Oncology completes first commercial sale of leukemia drug By Investing.com - Investing.com India
First U.S. commercial sale of Komzift triggers $135 million milestone payment to Kura Oncology - MarketScreener
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - The Manila Times
Kura Oncology (Nasdaq: KURA) to receive $135M as KOMZIFTI launches in U.S. market - Stock Titan
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 - GlobeNewswire
How Kura Oncology Inc. stock trades during market volatilityRate Hike & Daily Growth Stock Investment Tips - Newser
How geopolitical tensions affect Kura Oncology Inc. stockWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
How rising interest rates impact Kura Oncology Inc. stock - Newser
What drives Kura Oncology Inc stock priceSector Performance Drivers & Swing Trade Smarter With Data Insights - earlytimes.in
Magnetar Financial LLC Buys 64,345 Shares of Kura Oncology, Inc. $KURA - MarketBeat
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology’s leukemia drug added to NCCN treatment guidelines By Investing.com - Investing.com Australia
Kura Oncology’s leukemia drug added to NCCN treatment guidelines - Investing.com UK
Kura Oncology stock rises after KOMZIFTI added to NCCN treatment guidelines - Investing.com Canada
Kura Oncology and Kyowa Kirin's KOMZIFTI™ Approved and Included in NCCN Guidelines for Treatment of Relapsed/Refractory AML with NPM1 Mutation - Quiver Quantitative
KOMZIFTI™ (ziftomenib) Added to National Comprehensive - GlobeNewswire
Kura Oncology (NASDAQ: KURA) KOMZIFTI Named NCCN Category 2A Option for R/R NPM1 AML - Stock Titan
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed - Yahoo Finance
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Barclays Raises Price Target for Kura Oncology (KURA) to $28 | K - GuruFocus
Barclays Maintains Kura Oncology (KURA) Overweight Recommendation - MSN
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement - MSN
Is Kura Oncology Inc a good long term investmentMarket Entry Points & Free Exceptional Risk Adjusted Gains - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades - Yahoo Finance
(KURA) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Will Kura Oncology Inc. stock benefit from infrastructure spendingQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
How Kura Oncology Inc. stock performs in high volatility marketsEarnings Growth Summary & Long-Term Safe Investment Plans - newser.com
Kura Oncology at Jefferies Conference: Strategic Insights on Zypto By Investing.com - Investing.com Canada
Can Kura Oncology Inc. stock resist market sell offs2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Is Kura Oncology Inc. showing signs of accumulationQuarterly Market Summary & High Return Stock Watch Alerts - newser.com
Is Kura Oncology Inc. stock recession proofJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
How to monitor Kura Oncology Inc. with trend dashboards2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Candlestick signals on Kura Oncology Inc. stock todayJuly 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
Can Kura Oncology Inc. stock resist sector downturnsRecession Risk & Daily Growth Stock Investment Tips - newser.com
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):